Please login to the form below

Not currently logged in

Medicine adherence linked to doctor-patient communications

Patients’ trust and confidence in HCP impacts on adherence, according to US study

Diabetic patients whose doctors possess good communications skills adhere better to medicine programmes, according to a new US study.

The Diabetes Study of North California involved 9,000 patients with diabetes and used a 10-point scoring system to assess healthcare professional's communications skills.

The researchers found that patients of healthcare professionals (HCPs) who scored low on the rating for involving patients in decisions, understanding a patient's problems with treatment and eliciting trust and confidence were more likely to have poor adherence, compared to those with higher ratings.

“Poor communication ratings were independently associated with objectively measured inadequate cardiometabolic medication refill adherence,” said Neda Ratanawongsa, MD, MPH.

Ratanawongsa went on to say that future studies should examine whether communication interventions for HCPs with poor communication scores could improve their patient's adherence.

14th January 2013

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...